Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Location
200 3650 Gilmore Way, Burnaby, British Columbia, Canada
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.57K % -36.7%
Debt-to-equity 6.45 % +52.5%
Return On Equity -46.2 % -87.1%
Return On Assets -43.4 % -83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.3M shares +1.36%
Common Stock, Shares, Outstanding 77.1M shares +1.75%
Entity Public Float 2.95B USD +20.6%
Common Stock, Value, Issued 1.48B USD +2.33%
Weighted Average Number of Shares Outstanding, Basic 79.2M shares +1.7%
Weighted Average Number of Shares Outstanding, Diluted 79.2M shares +1.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 273M USD +42%
General and Administrative Expense 75.6M USD +19%
Operating Income (Loss) -341M USD -33.4%
Nonoperating Income (Expense) 31.1M USD -25.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -310M USD -44.8%
Income Tax Expense (Benefit) -3.37M USD -656%
Net Income (Loss) Attributable to Parent -306M USD -43.6%
Earnings Per Share, Basic -3 USD/shares -37.1%
Earnings Per Share, Diluted -3 USD/shares -37.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 105M USD +19.3%
Marketable Securities, Current 358M USD -36.8%
Accounts Receivable, after Allowance for Credit Loss, Current 1.47M USD +68.1%
Assets, Current 480M USD -27.2%
Deferred Income Tax Assets, Net 11.8M USD +1015%
Property, Plant and Equipment, Net 8.89M USD -12.5%
Operating Lease, Right-of-Use Asset 6.96M USD -15.7%
Assets 608M USD -27.3%
Employee-related Liabilities, Current 11.1M USD +24.1%
Liabilities, Current 38.3M USD +29.1%
Operating Lease, Liability, Noncurrent 6.83M USD -18.7%
Other Liabilities, Noncurrent 3.16M USD
Liabilities 48.3M USD +26.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 477K USD -64.3%
Retained Earnings (Accumulated Deficit) -1.14B USD -36.7%
Stockholders' Equity Attributable to Parent 560M USD -29.9%
Liabilities and Equity 608M USD -27.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -61.7M USD -33.5%
Net Cash Provided by (Used in) Financing Activities 1.15M USD
Net Cash Provided by (Used in) Investing Activities 34.5M USD
Common Stock, Shares, Issued 77.1M shares +1.75%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26.1M USD +71%
Deferred Tax Assets, Valuation Allowance 267M USD +24.4%
Deferred Tax Assets, Gross 279M USD +28%
Operating Lease, Liability 8.33M USD -14.9%
Payments to Acquire Property, Plant, and Equipment 43K USD -77.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -307M USD -46.9%
Lessee, Operating Lease, Liability, to be Paid 9.27M USD -16.4%
Operating Lease, Liability, Current 1.5M USD +7.79%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.79M USD -1.32%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.8M USD +3.21%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) -1.21M USD -401%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 947K USD -27.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.09M USD -39.5%
Deferred Tax Assets, Operating Loss Carryforwards 173M USD +44.7%
Unrecognized Tax Benefits 10.9M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.14M USD +3.45%
Operating Lease, Payments 420K USD +2.19%
Deferred Tax Assets, Net of Valuation Allowance 9.67M USD +1105%
Share-based Payment Arrangement, Expense 53.2M USD +5.41%